SPGL008 / 3SBio - LARVOL DELTA

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG. (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Monotherapy • New P1/2 trial • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Solid Tumor

A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=96 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Monotherapy • New P1 trial • Solid Tumor